C
A
Last name: CHALABI
First name: Asma
International audience
Cell response heterogeneity upon treatment is the main obstacle in developing efficacious cancer drugs in preclinical research. Although single-cell tudies have revealed the depth of cellular heterogeneity observed between in tumor cells, the regulatory impact of cell variability on therapeutic esponse remains unclear.To gain a deeper...
Cell response heterogeneity upon treatment is a main obstacle in preclinical development of efficacious cancer drugs, due to the emergence of drug-tolerant cells. We have previously developed a single-cell workflow, Fate-Seq (1,2), to profile drug-tolerant persisters. Fate-Seq is based on the prediction of the drug response of each cells that...
International audience
Cell response variability is a starting point in cancer drug resistance that has been difficult to analyze because the tolerant cell states are short lived. Here, we present fate-seq, an approach to isolate single cells in their transient states of drug sensitivity or tolerance before profiling. The drug response is predicted in live cells,...
Cell response variability is a starting point in cancer drug resistance that has been difficult to analyze because the tolerant cell states are short lived. Here, we present fate-seq, an approach to isolate single cells in their transient states of drug sensitivity or tolerance before profiling. The drug response is predicted in live cells,...
International audience